다른 서비스와 비교했을 때 CRNX 의 PB 비율은 어느 정도인가요?

CRNX은 Price-To-Book 비율(6.4x)을 기준으로 볼 때 동종 업계 평균(10x)과 비교했을 때 좋은 가치를 가지고 있습니다.

CRNX 의 PB 비율은 US Biotechs 업계의 다른 회사와 어떻게 비교됩니까?

CRNX 은 US Biotechs 과 비교하여 Price-To-Book 비율( 6.4 x)을 기준으로 비용이 많이 듭니다. Biotechs 업계 평균( 1.9 x).

CRNX 의 PB 비율과 공정 PB 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PB 비율입니다.

평가 분석을 위한 CRNX 의 Price-To-Book 공정 비율을 계산하기에는 데이터가 부족합니다.

미래 현금 흐름을 볼 때 CRNX 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

평가 분석을 위해 CRNX 의 공정 가치를 계산하기에는 데이터가 부족합니다.

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

목표주가는 현재 주가보다 20 % 이상 높지만, 애널리스트들은 통계적으로 신뢰하는 합의 범위 내에 있지 않습니다.

Crinetics Pharmaceuticals (Nasdaq:CRNX) - 주가, 뉴스 및 분석

CRNX 주식 개요

임상 단계의 제약 회사인 크리네틱스 파마슈티컬스는 희귀 내분비 질환 및 내분비 관련 종양에 대한 새로운 치료제의 발견, 개발 및 상용화에 주력하는 회사입니다. 자세한 내용

CRNX 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 67.68% 증가할 것으로 예상됩니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 수익이 없습니다. ( $1M )

Crinetics Pharmaceuticals, Inc. 경쟁사

Ionis Pharmaceuticals

NasdaqGS:IONS

US$5.6b

IVERIC bio

NasdaqGS:ISEE

US$5.5b

Viking Therapeutics

NasdaqCM:VKTX

US$6.0b

Biohaven

NYSE:BHVN

US$4.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Crinetics Pharmaceuticals
과거 주가
현재 주가	US$57.67
52주 최고치	US$62.53
52주 최저치	US$31.35
베타	0.62
11개월 변경	0.91%
3개월 변경 사항	9.43%
1년 변경 사항	80.05%
33년 변화	131.98%
5년 변화	197.27%
IPO 이후 변화	135.29%

최근 뉴스 및 업데이트

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

주주 수익률

	CRNX	US Biotechs	US 마켓
7D	2.9%	4.3%	1.6%
1Y	80.1%	18.8%	32.3%

수익률 대 산업: CRNX 지난 1년 동안 18.8 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: CRNX 지난 1년 동안 32.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is CRNX's price volatile compared to industry and market?
CRNX volatility
CRNX Average Weekly Movement	5.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: CRNX 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: CRNX 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2008	290	R. Struthers	www.crinetics.com

임상 단계 제약 회사인 크리네틱스 파마슈티컬스는 희귀 내분비 질환 및 내분비 관련 종양에 대한 새로운 치료제의 발견, 개발 및 상용화에 주력하고 있습니다. 회사의 주요 제품 후보로는 경구용 선택적 비펩타이드 소마토스타틴 수용체 2형 작용제인 팔투소틴이 있으며, 말단비대증 치료를 위한 임상 3상 시험과 신경내분비 종양과 관련된 카르시노이드 증후군 치료를 위한 임상 2상 시험을 진행 중입니다. 또한 부신피질자극호르몬(ACTH) 수용체를 길항하는 경구용 비펩타이드 신약 후보물질 CRN04894를 개발 중이며, 선천성 부신 과형성 및 쿠싱병 등 ACTH 과다로 인한 질환 치료를 위한 임상 1상 시험을 완료했습니다.

Crinetics Pharmaceuticals, Inc. 기본 사항 요약

Crinetics Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CRNX 기본 통계
시가총액	US$5.26b
수익(TTM)	-US$277.91m
수익(TTM)	US$1.04m

5,147x

P/S 비율

-19.2x

P/E 비율

CRNX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CRNX 손익 계산서(TTM)
수익	US$1.04m
수익 비용	US$50.64m
총 이익	-US$49.60m
기타 비용	US$228.31m
수익	-US$277.91m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-3.00
총 마진	-4,774.21%
순이익 마진	-26,747.83%
부채/자본 비율	0%

CRNX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CRNX 주식 개요

보상

위험 분석

Crinetics Pharmaceuticals, Inc. 경쟁사

NasdaqGS:IONS

US$5.6b

NasdaqGS:ISEE

US$5.5b

NasdaqCM:VKTX

US$6.0b

NYSE:BHVN

US$4.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Recent updates

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Chief Operating Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index

Chief Commercial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Price target increased by 7.8% to US$66.43

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Price target increased by 8.2% to US$61.50

Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022)

Founder notifies of intention to sell stock

Price target increased by 10% to US$59.79

Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

Chief Development Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.8% to US$57.23

Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly

Price target increased by 9.1% to US$54.46

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Consensus revenue estimates decrease by 88%, EPS upgraded

Consensus revenue estimates decrease by 89%, EPS upgraded

Chief Medical Officer notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Chief Medical Officer notifies of intention to sell stock

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly

Price target increased by 8.2% to US$46.78

Consensus revenue estimates fall by 18%

Price target decreased by 7.4% to US$43.63

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Founder recently sold US$1.0m worth of stock